Zobrazeno 1 - 10
of 178
pro vyhledávání: '"Masayoshi Tsubuki"'
Autor:
Takahiro Tougan, Kazunori Takahashi, Mayumi Ikegami-Kawai, Masako Horiuchi, Shiho Mori, Maiko Hosoi, Toshihiro Horii, Masataka Ihara, Masayoshi Tsubuki
Publikováno v:
Malaria Journal, Vol 18, Iss 1, Pp 1-12 (2019)
Abstract Background Basic blue 3 is a promising anti-malarial lead compound based on the π-delocalized lipophilic cation hypothesis. Its derivatives with nitrogen atoms bonded to carbon atoms at the 3- and 7-positions on the phenoxazine ring were pr
Externí odkaz:
https://doaj.org/article/e07c6fc9cddb4345b47970b509787a90
Autor:
Atsushi Furuta, Masayoshi Tsubuki, Miduki Endoh, Tatsuki Miyamoto, Junichi Tanaka, Kazi Abdus Salam, Nobuyoshi Akimitsu, Hidenori Tani, Atsuya Yamashita, Kohji Moriishi, Masamichi Nakakoshi, Yuji Sekiguchi, Satoshi Tsuneda, Naohiro Noda
Publikováno v:
International Journal of Molecular Sciences, Vol 16, Iss 8, Pp 18439-18453 (2015)
Hepatitis C virus (HCV) is an important etiological agent of severe liver diseases, including cirrhosis and hepatocellular carcinoma. The HCV genome encodes nonstructural protein 3 (NS3) helicase, which is a potential anti-HCV drug target because its
Externí odkaz:
https://doaj.org/article/335ad083a37c4296872a1cb1855a34d0
Autor:
Kazi Abdus Salam, Atsushi Furuta, Naohiro Noda, Satoshi Tsuneda, Yuji Sekiguchi, Atsuya Yamashita, Kohji Moriishi, Masamichi Nakakoshi, Hidenori Tani, Sona Rani Roy, Junichi Tanaka, Masayoshi Tsubuki, Nobuyoshi Akimitsu
Publikováno v:
Molecules, Vol 19, Iss 4, Pp 4006-4020 (2014)
The helicase portion of the hepatitis C virus nonstructural protein 3 (NS3) is considered one of the most validated targets for developing direct acting antiviral agents. We isolated polybrominated diphenyl ether (PBDE) 1 from a marine sponge as an N
Externí odkaz:
https://doaj.org/article/eae347ac00ca414684d71b216c0593a4
Autor:
Atsushi Furuta, Kazi Abdus Salam, Idam Hermawan, Nobuyoshi Akimitsu, Junichi Tanaka, Hidenori Tani, Atsuya Yamashita, Kohji Moriishi, Masamichi Nakakoshi, Masayoshi Tsubuki, Poh Wee Peng, Youichi Suzuki, Naoki Yamamoto, Yuji Sekiguchi, Satoshi Tsuneda, Naohiro Noda
Publikováno v:
Marine Drugs, Vol 12, Iss 1, Pp 462-476 (2014)
Hepatitis C virus (HCV) is an important etiological agent that is responsible for the development of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. HCV nonstructural protein 3 (NS3) helicase is a possible target for novel drug deve
Externí odkaz:
https://doaj.org/article/938becb12fd0415aa67046233a4f8b5f
Autor:
Naohiro Noda, Nobuyoshi Akimitsu, Yuji Sekiguchi, Satoshi Tsuneda, Masamichi Nakakoshi, Masayoshi Tsubuki, Nobuyuki Enomoto, Shinya Maekawa, Naoya Sakamoto, Nobuyuki Kato, Masanori Ikeda, Yuusuke Fujimoto, Hidenori Tani, Yoshihisa Fujita, Osamu Fujita, Yasuyoshi Matsuda, Atsushi Furuta, Kazi Abdus Salam, Atsuya Yamashita, Junichi Tanaka, Kohji Moriishi
Publikováno v:
Marine Drugs, Vol 10, Iss 4, Pp 744-761 (2012)
Hepatitis C virus (HCV) is a causative agent of acute and chronic hepatitis, leading to the development of hepatic cirrhosis and hepatocellular carcinoma. We prepared extracts from 61 marine organisms and screened them by an in vitro fluorescence ass
Externí odkaz:
https://doaj.org/article/edd9a598b9c4400bacd28c66ac07e9cd
Autor:
Hui Shen, Atsuya Yamashita, Masamichi Nakakoshi, Hiromasa Yokoe, Masashi Sudo, Hirotake Kasai, Tomohisa Tanaka, Yuusuke Fujimoto, Masanori Ikeda, Nobuyuki Kato, Naoya Sakamoto, Hiroko Shindo, Shinya Maekawa, Nobuyuki Enomoto, Masayoshi Tsubuki, Kohji Moriishi
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e82299 (2013)
Caffeic acid phenethyl ester (CAPE) has been reported as a multifunctional compound. In this report, we tested the effect of CAPE and its derivatives on hepatitis C virus (HCV) replication in order to develop an effective anti-HCV compound. CAPE and
Externí odkaz:
https://doaj.org/article/ddfd662c7e9d4a3695a840702b340621
Autor:
Yuusuke Fujimoto, Kazi Abdus Salam, Atsushi Furuta, Yasuyoshi Matsuda, Osamu Fujita, Hidenori Tani, Masanori Ikeda, Nobuyuki Kato, Naoya Sakamoto, Shinya Maekawa, Nobuyuki Enomoto, Nicole J de Voogd, Masamichi Nakakoshi, Masayoshi Tsubuki, Yuji Sekiguchi, Satoshi Tsuneda, Nobuyoshi Akimitsu, Naohiro Noda, Atsuya Yamashita, Junichi Tanaka, Kohji Moriishi
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e48685 (2012)
Combination therapy with ribavirin, interferon, and viral protease inhibitors could be expected to elicit a high level of sustained virologic response in patients infected with hepatitis C virus (HCV). However, several severe side effects of this com
Externí odkaz:
https://doaj.org/article/d09c1071b1154cf6977a9ea8a2ce3cb6
Autor:
Hiromasa Yokoe, Akiko Kiriyama, Miho Shimoda, Satoru Nakajima, Yuna Hashizume, Yuto Endo, Ryoko Iwamoto, Masayoshi Tsubuki, Naoki Kanoh
Publikováno v:
The Journal of Organic Chemistry. 88:1803-1814
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a60d24d1285b647c38915d04f30e7153
https://doi.org/10.1021/acs.joc.2c02225
https://doi.org/10.1021/acs.joc.2c02225
Autor:
Hiromasa Yokoe, Akiko Kiriyama, Miho Shimoda, Satoru Nakajima, Yuna Hashizume, Yuto Endo, Ryoko Iwamoto, Masayoshi Tsubuki, Naoki Kanoh
Spiro compounds have been considered key scaffolds for pharmaceutical applications. Although many synthetic meth-ods exist for monospirocycles, fewer approaches are known for dispirocycles. Here, we report a highly cis-selective method for constructi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e00d56a052b3e967947c222ef3828aa
https://doi.org/10.26434/chemrxiv-2022-h15hv-v2
https://doi.org/10.26434/chemrxiv-2022-h15hv-v2
Autor:
Atsuya Yamashita, Kaori Okuyama-Dobashi, Kazunori Takahashi, Ryoji Motohashi, Hiromasa Yokoe, Kohji Moriishi, Akihide Ryo, Pattama Wiriyasermkul, Tomohisa Tanaka, Shinya Maekawa, Hirotake Kasai, Masayoshi Tsubuki, Nobuyuki Enomoto, Shushi Nagamori
Publikováno v:
Antiviral research. 194
The development of novel antivirals to treat hepatitis B virus (HBV) infection is still needed because currently available drugs do not completely eradicate chronic HBV in some patients. Recently, troglitazone and ciglitazone, classified among the co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bfb7f47b8068a5bee82900c3d182a2d
https://pubmed.ncbi.nlm.nih.gov/34419484
https://pubmed.ncbi.nlm.nih.gov/34419484